Why gene-therapy drugs are so expensive
By N.L.,
The Economist
| 08. 03. 2016
Untitled Document
On August 3rd the British pharmaceutical company GSK said that it would charge €594,000 ($665,000) for a gene-therapy cure for ADA-SCID—a severe immune disorder that is usually fatal in the first few years of life. A child born with ADA-SCID is unable to fight off everyday infections; Strimvelis has cured this in each of the 18 children it has been tested on over 15 years. Gene therapies work by delivering correct versions of DNA, usually using a virus as a vector. Once DNA is inside the cell, it produces the protein that was missing and the fault is fixed. Scientists have been trying to develop gene therapies for decades. Early work hit the buffers due to a series of unexpected cancers, the death of a young man during a trial, and some disappointing results.
Much progress has been made since then and according to analysts at Datamonitor Healthcare the number of gene therapies in development has doubled since 2012. Last week, America’s Food and Drug Administration (FDA) handed out “breakthrough” designations—intended to hasten the approval of important new...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jonquilyn Hill, Vox | 10.18.2026
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...